中文摘要：

目的探讨E2F1、BIRC5在恶性淋巴瘤中的表达情况及其临床意义。方法应用免疫组织化学SP法检测90例恶性淋巴瘤及15例淋巴组织反应性增生中E2F1、BIRC5蛋白的表达。结果恶性淋巴瘤中E2F1、BIRC5蛋白表达阳性率显著高于反应性增生组中的表达（P〈0.05）。E2F1、BIRC5蛋白在侵袭性及高侵袭性淋巴瘤中的表达显著高于惰性淋巴瘤中的表达（P〈0.01）,而两者在侵袭性与高侵袭性淋巴瘤中的表达差异无显著性（P〉0.05）。E2F1、BIRC5蛋白在Ⅲ期和Ⅳ期患者中的表达显著高于Ⅰ期和Ⅱ期中的表达（P〈0.01）。此外,经统计学分析,E2F1、BIRC5蛋白在不同性别、年龄、发生部位、组织学类型组中的表达差异均无显著性（P〉0.05）。经Spearman等级相关分析,E2F1与BIRC5蛋白在恶性淋巴瘤中的表达呈显著正相关（P〈0.01）。结论 E2F1和BIRC5的高表达可能是恶性淋巴瘤发生发展的重要生物学标志。

英文摘要：

Objective To investigate the expression of E2F1,BIRC5 in malignant lymphomas and their clinical significances.Methods The expression of E2F1,BIRC5 were detected in 90 cases of malignant lymphomas and 15 cases of reactive hyperplasia Lymph node by immunohistochemistry.Results E2F1and BIRC5 positive rate of malignant lymphomas were higher than those in reactive hyperplasia Lymph node.（P0.05）.The E2F1and BIRC5 positive rate of aggressive lymphoma and high aggressive lymphoma were higher than that in indolent lymphoma（P0.01）,but the difference between.aggressive and high aggressive lymphoma was not significant（P0.05）.E2F1 and BIRC5 positive rate of phase Ⅲ and Ⅳclinical stage lymphoma were much higher than those in phase Ⅰ and Ⅱ clinical stage lymphoma（P0.01）.And the difference of E2F1 and BIRC5 expressions in different age,gender,occurrence site and histological type were not significant（P0.05）.And the expression of E2F1 was positively correlated with the expression of BIRC5（P0.01）.Conclusion The higher expression of E2F1 and BIRC5 may be important biological markers for the development and progression of malignant lymphoma.